Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in Adults With Symptomatic Obstructive HCM Eligible for SRT
NCT04349072Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Bristol Myers Squibb. Started Jul 2020; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT04349072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349072.